Department of Paediatrics, Faculty of Clinical Sciences, College of Medicine, University of Ibadan, Oyo State, Nigeria; Department of Paediatrics, University College Hospital Ibadan, Oyo State, Nigeria.
Department of Paediatrics, Faculty of Clinical Sciences, College of Medicine, University of Ibadan, Oyo State, Nigeria; Department of Paediatrics, University College Hospital Ibadan, Oyo State, Nigeria.
Semin Nephrol. 2022 Sep;42(5):151311. doi: 10.1016/j.semnephrol.2023.151311. Epub 2023 Mar 9.
Nephrotic syndrome is a common childhood glomerular disease that is associated with massive proteinuria and edema. Children with nephrotic syndrome are at risk of chronic kidney disease, disease-related complications, and treatment-related complications. Patients with frequently relapsing disease or steroid toxicity may require newer immunosuppressive medications. However, access to these medications is limited in many African countries owing to prohibitive cost, the need for frequent therapeutic drug monitoring, and a lack of appropriate facilities. This narrative review examines the epidemiology of childhood nephrotic syndrome in Africa, including trends in treatment and patient outcomes. In most of North Africa, as well as among White and Indian populations in South Africa, the epidemiology and treatment of childhood nephrotic syndrome closely resembles that of European and North American populations. Historically, secondary causes of nephrotic syndrome (eg, quartan malaria nephropathy and hepatitis B-associated nephropathy) were predominant among Blacks in Africa. Over time, the proportion of secondary cases has decreased, along with rates of steroid resistance. However, focal segmental glomerulosclerosis increasingly has been reported among patients with steroid resistance. There is a need for consensus guidelines for the management of childhood nephrotic syndrome in Africa. Furthermore, establishing an African nephrotic syndrome registry could facilitate monitoring of disease and treatment trends, and provide opportunities for advocacy and research to improve patient outcomes.
肾病综合征是一种常见的儿童肾小球疾病,其特征是大量蛋白尿和水肿。肾病综合征患儿存在慢性肾脏病、疾病相关并发症和治疗相关并发症的风险。频繁复发疾病或类固醇毒性的患者可能需要新型免疫抑制药物。然而,由于成本高昂、需要频繁的治疗药物监测以及缺乏适当的设施,这些药物在许多非洲国家都无法获得。本综述探讨了非洲儿童肾病综合征的流行病学,包括治疗趋势和患者结局。在北非的大部分地区以及南非的白人和印度人群中,儿童肾病综合征的流行病学和治疗方法与欧洲和北美的人群相似。历史上,肾病综合征的继发原因(如间日疟肾病和乙型肝炎相关性肾病)在非洲黑人中较为常见。随着时间的推移,继发病例的比例以及类固醇耐药率均有所下降。然而,类固醇耐药患者中局灶节段性肾小球硬化的报道越来越多。非洲需要制定儿童肾病综合征管理的共识指南。此外,建立非洲肾病综合征登记处可以有助于监测疾病和治疗趋势,并为改善患者结局提供宣传和研究机会。